Privately-held biopharma Tizona Therapeutics Inc. got its New Year off to a good start by unveiling an early-stage cancer R&D collaboration with AbbVie Inc. by which the San Francisco-based biotech will receive a $105m upfront cash payment plus an equity injection from the big pharma.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?